Looking to expand your partner network with the latest in the field of dystrophic epidermolysis bullosa? Consider joining Inpart's global network for free.
News and Trends 22 May 2023
FDA approves first topical gene therapy for dystrophic epidermolysis bullosa wound treatment
The U.S. Food and Drug Administration has approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene. The approval of Vyjuvek was granted to […]
